Rossari Biotech Limited — Updates, 20-10-2024: Press Release

Rossari Biotech Limited reported a steady Q2 FY25 performance, with revenue growing 3.1% to Rs. 498.4 crore and a 7.3% increase in PAT to Rs. 35.3 crore. Key developments include the acquisition of Unistar and the establishment of a subsidiary in the UAE, aimed at expanding global operations. The company also purchased land for future expansion and appointed Mr. Gurudas Aras as a Non-Executive Independent Director, enhancing its strategic capabilities and governance.